Skip to main content

Table 1 Biochemical findings

From: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model

Treatment

Liver function biomarkers

Kidney function biomarkers

AST (Unit/L)

ALT (Unit/L)

Bilirubin (mg/dl)

BUN (mg/dl)

Creatinine (mg/dl)

PBS

168 ± 63.3

67 ± 27.5

0.1

27.0 ± 1.7

0.21 ± 0.02

Ad-ΔB

190 ± 36.4

52 ± 17.8

0.1

29.3 ± 5.5

0.20 ± 0.01

Ad-ΔB/TRAIL + Ad-ΔB/IL-12

118 ± 12.5

52 ± 42.2

0.2

30.6. ± 2.1

0.21 ± 0.02

  1. HCC-bearing mice were systemically treated with PBS, controlled non-armed Ad-ΔB, or combination of Ad-ΔB/TRAIL+Ad-ΔB/IL-12; at a dosage regimen of 1 × 1010 VP/intravenous injection; three times every other day. 72 h after the last dose, serum levels of hepato-renal function biomarkers of each group were assessed. Data are represented as mean ± SE
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us